Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors
Non-Hodgkin lymphomas comprise a heterogenous group of disorders which differ in biology. Although response rates are high in some groups, relapsed disease can be difficult to treat, and newer approaches are needed for this patient population. It is increasingly apparent that the immune system plays...
Saved in:
Main Authors: | Maansi Joshi, Stephen M. Ansell |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2020/8820377 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Predictive biomarkers of response to immune checkpoint inhibitors
by: María Sacramento Díaz-Carrasco, et al.
Published: (2020-07-01) -
Targeting IL-33 in patients with cancer under immune checkpoint inhibitors for a better antitumor response and prevent thromboembolism?
by: Gianluca Azzellino, et al.
Published: (2025-02-01) -
Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity
by: Brian S Henick, et al.
Published: (2024-03-01) -
Unleashing immunity against oral cancer with immune checkpoint inhibitors
by: Ajay Guru
Published: (2024-06-01) -
Peripheral T Cell Non-Hodgkin’s Lymphoma following Treatment of Hodgkin’s Lymphoma
by: Sun Hee Chang, et al.
Published: (2015-01-01)